• Western blot analysis of lysates from NIH/3T3 cells, using MAGEA5 Antibody. The lane on the right is blocked with the synthesized peptide.
  • Western blot analysis of the lysates from K562 cells using MAGEA5 antibody.
  • Western blot analysis of 3T3 cells using MAGE-A5 Polyclonal Antibody

Anti-MAGEA5P antibody (68-117 aa) (STJ93990)

SKU:
STJ93990

Current Stock:
Host: Rabbit
Applications: WB/ELISA
Reactivity: Human/Rat/Mouse
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Rabbit polyclonal antibody anti-Putative melanoma-associated antigen 5P (68-117 aa) is suitable for use in Western Blot and ELISA research applications.
Clonality: Polyclonal
Conjugation: Unconjugated
Isotype: IgG
Formulation: Liquid in PBS containing 50% Glycerol, 0.5% BSA and 0.02% Sodium Azide.
Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration: 1 mg/mL
Dilution Range: WB 1:500-1:2000
ELISA 1:10000
Storage Instruction: Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles.
Gene Symbol: MAGEA5P
Gene ID: 100533997
Uniprot ID: MAGA5_HUMAN
Immunogen Region: 68-117 aa
Specificity: MAGE-A5 Polyclonal Antibody detects endogenous levels of MAGE-A5 protein.
Immunogen: The antiserum was produced against synthesized peptide derived from the human MAGEA5 at the amino acid range 68-117
Function May negatively regulates apoptosis.
Protein Name Putative Melanoma-Associated Antigen 5p
Cancer/Testis Antigen 1.5
Ct1.5
Mage Family Member A5 Pseudogene
Mage-5 Antigen
Alternative Antibody Names Anti-Putative Melanoma-Associated Antigen 5p antibody
Anti-Cancer/Testis Antigen 1.5 antibody
Anti-Ct1.5 antibody
Anti-Mage Family Member A5 Pseudogene antibody
Anti-Mage-5 Antigen antibody
Anti-MAGEA5P antibody
Anti-MAGE5 antibody
Anti-MAGEA5 antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance